VCI Wealth Management LLC Acquires 18,234 Shares of Johnson & Johnson $JNJ

VCI Wealth Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2,053.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,122 shares of the company’s stock after purchasing an additional 18,234 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of VCI Wealth Management LLC’s holdings, making the stock its 19th largest position. VCI Wealth Management LLC’s holdings in Johnson & Johnson were worth $5,062,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Garde Capital Inc. lifted its holdings in Johnson & Johnson by 15.3% in the third quarter. Garde Capital Inc. now owns 2,976 shares of the company’s stock worth $788,000 after purchasing an additional 395 shares during the period. Gerber Kawasaki Wealth & Investment Management grew its position in Johnson & Johnson by 15.8% in the 3rd quarter. Gerber Kawasaki Wealth & Investment Management now owns 6,438 shares of the company’s stock valued at $1,704,000 after buying an additional 879 shares in the last quarter. GRIMES & Co WEALTH MANAGEMENT LLC grew its position in Johnson & Johnson by 1.1% in the 3rd quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 121,668 shares of the company’s stock valued at $32,211,000 after buying an additional 1,305 shares in the last quarter. BOCHK Asset Management Ltd increased its stake in Johnson & Johnson by 30.2% during the 3rd quarter. BOCHK Asset Management Ltd now owns 19,900 shares of the company’s stock valued at $5,268,000 after buying an additional 4,610 shares during the period. Finally, Blue Bell Private Wealth Management LLC increased its stake in Johnson & Johnson by 6.0% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 13,338 shares of the company’s stock valued at $3,531,000 after buying an additional 753 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.6%

Shares of Johnson & Johnson stock opened at $266.10 on Wednesday. The business has a fifty day simple moving average of $265.60 and a 200-day simple moving average of $247.46. Johnson & Johnson has a fifty-two week low of $185.12 and a fifty-two week high of $282.02. The firm has a market cap of $640.59 billion, a price-to-earnings ratio of 40.32, a price-to-earnings-growth ratio of 2.67 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Analyst Upgrades and Downgrades

A number of analysts have commented on JNJ shares. Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Bank of America reiterated a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Tuesday, September 29th. Finally, Morgan Stanley dropped their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $275.92.

Insider Activity

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 64,515 shares of company stock worth $17,271,766. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at TCT 2026 linked Impella-supported high-risk coronary procedures with lower mortality than prior study benchmarks; one report also cited a 94% procedural success rate. The findings could bolster the case for the heart-pump business, though further evidence, including the ongoing PROTECT IV trial, remains important. Article: Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Neutral Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors, but its alert provides no details about the claims or any legal action. The announcement alone does not establish wrongdoing or the likely financial impact. Article: Pomerantz Law Firm investigates claims on behalf of investors of Johnson & Johnson
• Negative Sentiment: The investor investigation is a potential source of uncertainty and could weigh on sentiment if it develops into substantive litigation or reveals material allegations. Article: Pomerantz Law Firm investigates claims on behalf of investors of Johnson & Johnson

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.